Drug Profile
SQ 109
Alternative Names: NSC 722041; SQ109Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator National Institute of Allergy and Infectious Diseases; Sequella
- Developer Infectex; Ludwig-Maximilians-University; Sequella
- Class Anti-inflammatories; Antibacterials; Antifungals; Antituberculars; Antiulcers; Ethylenediamines; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Tuberculosis
- No development reported Duodenal ulcer; Helicobacter infections; Mycobacterial infections; Mycoses
- Discontinued Crohn's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Tuberculosis in USA (PO, Tablet)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Mycobacterial-infections in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in USA (Parenteral)